Tackling the thrombotic burden in patients with acute coronary syndrome and diabetes mellitus

Expert Review of Cardiovascular Therapy

Volumn 9, Issue 6, 2011, Pages 697-710

  Angiolillo, Dominick J ^a   Roffi, Marco ^b   Fernandez Ortiz, Antonio ^c  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

acute coronary syndromes; antiplatelet drugs; aspirin; clopidogrel; diabetes; P2Y12inhibitors; percutaneous coronary intervention; platelets; prasugrel; ticagrelor

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; APIXABAN; ATOPAXAR; CANGRELOR; CILOSTAZOL; CLOPIDOGREL; DABIGATRAN; ELINOGREL; EPTIFIBATIDE; HEPARIN; HIRULOG; INSULIN; PICOTAMIDE; PLACEBO; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; RAMATROBAN; RIDOGREL; RIVAROXABAN; TERUTROBAN; TICAGRELOR; TICLOPIDINE; TIROFIBAN; VORAPAXAR;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BLEEDING; CORONARY ARTERY BYPASS SURGERY; DIABETES MELLITUS; DRUG EFFICACY; DRUG ELUTING STENT; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG WITHDRAWAL; DYSPNEA; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART INFARCTION; HEART PALPITATION; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; MORTALITY; PATHOGENESIS; PERCUTANEOUS CORONARY INTERVENTION; RECEPTOR BLOCKING; REVIEW; RISK REDUCTION; STENT THROMBOSIS; THROMBOCYTE DYSFUNCTION; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; BLOOD PLATELETS; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; PLATELET AGGREGATION INHIBITORS; RECEPTORS, PURINERGIC P2Y12; THROMBOSIS;

EID: 79959912976     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.11.76     Document Type: Review

References (52)

1. Donahoe SM, Stewart GC, McCabe CH et al. Diabetes and mortality following acute coronary syndromes. JAMA 298(7), 765-775 (2007) (Pubitemid 47263159)
2. González EL, Johansson S, Wallander MA, Rodríguez LA. Trends in the prevalence and incidence of diabetes in the UK: 1996-2005. J. Epidemiol. Community Health 63(4), 332-336 (2009)
3. Amin AP, Marso SP. Acute coronary syndrome in the patient with diabetes: is the management different? Curr. Cardiol. Rep. 12(4), 321-329 (2010)
4. Bagust A, Hopkinson PK, Maslove L, Downs KE, Harrison DJ. Future prevalence and economic burden of Type 2 diabetes in the United States to 2050. Diabetes 50, A205 838 (2001)
5. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339(4), 229-234 (1998) (Pubitemid 28350165)
6. Kuchulakanti PK, Chu WW, Torguson R et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 113(8), 1108-1113 (2006)
7. Iakovou I, Schmidt T, Bonizzoni E et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293(17), 2126-2130 (2005) (Pubitemid 40617065)
8. Urban P, Gershlick AH, Guagliumi G et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation 113(11), 1434-1441 (2006) (Pubitemid 43739440)
9. Machecourt J, Danchin N, Lablanche JM et al. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT Matched-Cohort Registry. J. Am. Coll. Cardiol. 50(6), 501-508 (2007) (Pubitemid 47126769)
10. Wiviott SD, Braunwald E, Angiolillo DJ et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel - Thrombolysis in Myocardial Infarction 38. Circulation 118(16), 1626-1636 (2008)
11. Ferreiro JL, Angiolillo DJ. Diabetes and anti-platelet therapy in acute coronary syndrome. Circulation 123(7), 798-813 (2011)
12. Ueno M, Ferreiro JL, Tomasello SD et al. Functional profile of the platelet P2Y12 receptor signalling pathway in patients with Type 2 diabetes mellitus and coronary artery disease. Thromb. Haemost. 105(4), 105(4), 730-732 (2011)
13. Anfossi G, Russo I, Trovati M. Platelet dysfunction in central obesity. Nutr. Metab. Cardiovasc. Dis. 19(6), 440-449 (2009)
14. Roffi M, Chew DP, Mukherjee D et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation 104(23), 2767-2771 (2001) (Pubitemid 33126648)
15. Feit F, Manoukian SV, Ebrahimi R et al. Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: a report from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J. Am. Coll. Cardiol. 51(17), 1645-1652 (2008) (Pubitemid 351635836)
16. Antiplatelet Trialists' Collaboration Collaborative overview of randomized trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308(6921), 81-106 (1994)
17. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324(7329), 71-86 (2002).
18. Watala C, Pluta J, Golanski J et al. Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J. Mol. Med. 83(2), 148-158 (2005) (Pubitemid 40379303)
19. Davì G, Catalano I, Averna M et al. Thromboxane biosynthesis and platelet function in Type II diabetes mellitus. N. Engl. J. Med. 322 (25), 1769-1774 (1990) (Pubitemid 20194655)
20. Watala C, Golanski J, Pluta J et al. Reduced sensitivity of platelets from Type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. Thromb. Res. 113(2), 101-113 (2004) (Pubitemid 38534487)
21. Di Minno G, Silver MJ, Murphy S. Monitoring the entry of new platelets into the circulation after ingestion of aspirin. Blood 61(6), 1081-1085 (1983) (Pubitemid 13099894)
22. Riondino S, Trifirò E, Principessa L et al. Lack of biological relevance of platelet cyclooxygenase-2 dependent thromboxane A2 production. Thromb. Res. 122(3), 359-365 (2008)
23. Feletou M, Cohen RA, Vanhoutte PM, Verbeuren TJ. TP receptors and oxidative stress: hand in hand from endothelial dysfunction to atherosclerosis. In:Advances in Pharmacology (Volume 60)Vanhoutte PM (Ed.)Academic Press, MA, USA, 85-106 (2010)
24. Santilli F, Mucci L, Davì G. TP receptor activation and inhibition in atherothrombosis: the paradigm of diabetes mellitus. Intern. Emerg. Med. 6(3), 203-212 (2010)
25. DiChiara J, Bliden KP, Tantry US et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes 56(5), 3014-3019 (2007) (Pubitemid 350223637)
26. Capodanno D, Patel A, Dharmashankar K et al. Pharmacodynamic effects of different aspirin dosing regimens in Type 2 diabetes mellitus patients with coronary artery disease. Circ. Cardiovasc. Interv. 4(2), 180-187 (2011)
27. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345(7), 494-502 (2001) (Pubitemid 32758501)
28. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Platelet function profiles in patients with Type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 54(8), 2430-2435 (2005) (Pubitemid 41134272)
29. Angiolillo DJ, Bernardo E, Ramírez C et al. Insulin therapy is associated with platelet dysfunction in patients with Type 2 diabetes mellitus on dual oral antiplatelet treatment. J. Am. Coll. Cardiol. 48(2), 298-304 (2006) (Pubitemid 44026661)
30. Angiolillo DJ, Bernardo E, Capodanno D et al. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J. Am. Coll. Cardiol. 55(11), 1139-1146 (2010)
31. Angiolillo DJ, Shoemaker SB, Desai B et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 115(6), 708-716 (2007) (Pubitemid 46294761)
32. Angiolillo DJ, Costa MA, Shoemaker SB et al. Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment. Am. J. Cardiol. 101(4), 440-445 (2008) (Pubitemid 351210628)
33. Mehta SR, Tanguay JF, Eikelboom JW et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomized factorial trial. Lancet 376(9748), 1233-1243 (2010)
34. Angiolillo DJ, Capranzano P, Goto S et al. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur. Heart J. 29(18), 2202-2211 (2008)
35. Agewall S, Badimon L, Drouet L et al. Oral antiplatelet agents in ACS: from pharmacology to clinical differences Fundam. Clin. Pharmacol. DOI: 10.1111/j.1472-8206.2010.00890 (2010) (Epub ahead of print)
36. Norgard NB, Abu-Fadel M. Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Vasc. Health Risk Manag. 5, 873-882 (2009)
37. Wilson W, Gurvitch R, Ajani AE. Prasugrel: a novel platelet ADP P2Y receptor antagonist. Cardiovasc. Ther. 27(3), 194-198 (2009)
38. Angiolillo DJ, Badimon J, Saucedo JF et al. A pharmacodynamic comparison of prasugrel versus high dose clopidogrel in patients with Type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In Diabetes Mellitus (OPTIMUS)-3 trial. Eur. Heart J. 32(7), 838-846 (2011)
39. Wiviott SD, Braunwald E, McCabe CH Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357(20), 2001-2015 (2007) (Pubitemid 350106708)
40. Murphy SA, Antman EM, Wiviott SD et al. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur. Heart J. 29(20), 2473-2479 (2008)
41. Siddique A, Butt M, Shantsila E, Lip GYH. New antiplatelet drugs: beyond aspirin and clopidogrel. Int. J. Clin. Pract. 63(5), 776-789 (2009)
42. Gurbel PA, Bliden KP, Butler K et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 120(25), 2577-2585 (2009)
43. Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361(11), 1045-1057 (2009)
44. Cannon CP, Harrington RA, James S et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomized double-blind study. Lancet 375, 283-293 (2010)
45. James S, Angiolillo DJ, Cornel JH et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Eur. Heart J. 31, 3006-3016 (2010)
46. Wright RS, Anderson JL, Adams CD et al. 2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/non-ST- elevation myocardial infarction (updating the 2007 guideline)J. Am. Coll. Cardiol. 57(19), e215-e367 (2011)
47. Anderson JL, Adams CD, Antman EM et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction. Circulation 116(7), e148-e304 (2007)
48. Angiolillo DJ. Variability in responsiveness to oral antiplatelet therapy. Am. J. Cardiol. 103(Suppl. 3), 27A-34A (2009)
49. Michelson AD, Cattaneo M, Eikelboom JW et al. Platelet physiology subcommittee of the scientific and standardization committee of the international society on thrombosis and haemostasis; working group on aspirin resistance. aspirin resistance: position paper of the working group on aspirin resistance. J. Thromb. Haemost. 3(6), 1309-1311 (2005)
50. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J. Am. Coll. Cardiol. 49(14), 1505-1516 (2007) (Pubitemid 46517957)
51. Gurbel PA, Bliden KP, DiChiara J et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 115(25), 3156-3164 (2007) (Pubitemid 47012230)
52. Frelinger AL 3rd, Furman MI, Linden MD et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2- independent pathway: a 700-patient study of aspirin resistance. Circulation 113(25), 2888-2896 (2006). (Pubitemid 44297229)